Nobelpharma America, a wholly owned subsidiary of Tokyo-based Nobelpharma Co., Ltd., has chosen AllianceRx Walgreens Pharmacy and Total Care Rx to distribute Hyftor (sirolimus) topical gel, which is approved to treat patients six years and older with facial angiofibroma associated with tuberous sclerosis complex. The FDA approved Hyftor in April 2022, and Hyftor has orphan drug status for this indication.
Hyftor treats facial angiofibroma (commonly presenting as small, red or pink bumps on the face) in adults and pediatric patients with tuberous sclerosis complex (TSC) 6 years and older. In the U.S., approximately 50,000 people have TSC, and an estimated 40,000 have TSC-related facial angiofibroma, with most diagnosed as children.
AllianceRx Walgreens Pharmacy’s advanced analytical capabilities, pharmacy expertise and technology solutions enable providers, pharmaceutical manufacturers and health plans to deliver optimal health outcomes. Beyond providing access, AllianceRx Walgreens Pharmacy further supports patients through its Specialty360 therapy teams.
Total Care Rx is a progressive, independently owned pharmacy that has the capacity of a major chain with the personalized approach of a local pharmacy. Total Care Rx strives to assist providers in appropriately managing treatment regimens in an effort to maximize their therapeutic potential.
Total Care Rx is equipped to service patients across all disease types including: Cystic Fibrosis, HIV/AIDS, Neurology, Transplant Care, Pulmonology, Epilepsy, and Long-Term Care.
Takeaway: In the U.S., approximately 50,000 people have TSC, and an estimated 40,000 have TSC-related facial angiofibroma, with most diagnosed as children